Jorge E. Cortes, MD
Quizartinib, a novel small molecule FLT3 inhibitor, is moving through the pipeline of new drugs under development for patients with FLT3
-mutated acute myeloid leukemia (AML), part of a menu of targeted treatment options that is expanding as investigators learn more about the molecular heterogeneity of the disease.
Figure. Quizartinib in Adult Patients With Relapsed/Refractory AML2
“The results of the QuANTUM-R trial showed an improvement in survival. The hazard ratio was 0.76, essentially meaning an approximately 24% reduction in the risk of death during the observation period of the study,” said Jorge E. Cortes, MD, in an interview with OncologyLive®
... to read the full story